Susanne M. Scesney

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

Zehra Kaymakcalan, Paul Sakorafas, Sahana Bose et al. · Clinical Immunology · 2009 · 314 citations

Life Sciences, Immunology, Pharmacology +13

Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats

Chen‐Hao Yeh, Henry C. Marsh, Gerald Carson et al. · The Journal of Immunology · 1991 · 94 citations · Full text

Life Sciences, Immunology, Pathology +17

EFFECT OF REPETITIVE HIGH-DOSE TREATMENT WITH SOLUBLE COMPLEMENT RECEPTOR TYPE 1 AND COBRA VENOM FACTOR ON DISCORDANT XENOGRAFT SURVIVAL1,2

Daniel Candinas, Beth‐Ann Lesnikoski, Simon C. Robson et al. · Transplantation · 1996 · 59 citations

Life Sciences, Immunology, Pharmacology +16

COMPLEMENT ACTIVATION AS A CAUSE FOR PRIMARY GRAFT FAILURE IN AN ISOGENEIC RAT MODEL OF HYPOTHERMIC LUNG PRESERVATION AND TRANSPLANTATION

Yoshifumi Naka, Henry C. Marsh, Susanne M. Scesney et al. · Transplantation · 1997 · 56 citations

Medicine, Physiology, Surgery +17

Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules

Charles W. Rittershaus, Lawrence J. Thomas, David P. Miller et al. · Journal of Biological Chemistry · 1999 · 56 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14